INTRODUCTION Psoriasis is an inflammatory and chronic skin disease associated with obesity, cardiovascular diseases, diabetes and metabolic syndrome. Adipokines, as bioactive substances secreted from adipose tissue, are involved in various metabolic diseases. AIM To investigate the association between psoriasis severity and serum adiponectin and leptin levels in patients with psoriasis. MAT...

This study correlated assessment tools for evaluating the severity of skin, nail, and joint symptoms in patients with psoriasis (Pso) and psoriatic arthritis (PsA). Adults with plaque Pso (with or without PsA) were enrolled from four U.S. institutions. Patients were evaluated using a novel 10-area Linear Psoriasis Area and Severity Index (XL-PASI), Psoriatic Arthritis Assessment (PsAA), Psoriat...

This is an observational, longitudinal and retrospective study of a group of patients with moderate to severe plaque psoriasis whom had been treated with efaluzimab (1mg/Kg/week) for up to 20 weeks. Nevertheless, first dose of 0.7 mg/kg was given. The efficacy of the drug was evaluated by measuring the psoriasis area and severity index (PASI), the body surface area (BSA) and index of the qualit...

Please cite this article as: Feltes F, Macías del Toro E, Ramírez Bellver JL, Bernardez Guerra C. Terapia de mantenimiento con ciclosporina en pauta de fin de semana para psoriasis moderada. Actas Dermosifiliogr. 2015;106:583--584. ∗ Corresponding author. E-mail address: [email protected] (F. Feltes). The use of ciclosporin microemulsion in a weekend regimen has been proposed as an alterna...

BACKGROUND Efalizumab, a T-cell-targeted, recombinant, humanized, monoclonal IgG1 antibody, inhibits key T-cell-mediated steps in the pathogenesis of psoriasis. Efalizumab is approved for the treatment of moderate-to-severe chronic plaque psoriasis in adults in more than 50 countries. OBJECTIVES To evaluate the efficacy and safety of long-term, continuous efalizumab therapy in patients with p...

Psoriasis is a chronic, immune-mediated inflammatory disorder affecting 2--3% of general population, being both physically and emotionally debilitating. Due to the rapid advances in the understanding of psoriasis pathogenesis, several targeted medications, aiming specific components of the immune system, have been and are currently being developed. These biologic therapies are a major technolog...

and poster production/management fees paid for by Astellas.P2631 Group for research and assessment of psoriasis and psoriatic arthriti-seinternational multi-center psoriasis and psoriatic arthritis reliabilitytrial (GRAPPA-IMPART): Assessment of psoriasis, nail lesions, peripheralarthritis, and dactylitis Alice Gottlieb, MD, PhD, Tufts-New England Medical Center, Boston, MA, Uni...

Background: Psoriasis is a chronic-relapsing inflammatory skin disorder, in whose pathogenesis oxidative stress is suggested to be involved. Among different enzymes that play a role in maintaining the cellular redox balance, we aimed to assess the alteration of glutathione peroxidase (GPX) activity in cutaneous lesions and its correlation with the disease severity, firstly, to support the possi...

Introduction Herein, we developed an engineered extracellular vehicle (EV)-based method for ameliorating inflammatory responses in psoriasis.Methods EVs, derived from annexin A1 (ANXA1) overexpressing T cells, were co-extruded with M2 macrophage membrane to obtain EVs. In vitro, the effect of EVs on polarization was evaluated by real-time PCR. imiquimod (IMQ)-induced psoriasis-like mouse model,...

Photochemotherapy with psoralen plus ultraviolet A(PUVA) and phototherapy with UVB narrow band (UVB-NB) are used in the treatment of psoriasis. Numerous studies have shown that the additional administration of either topical or systemic antipsoriatic agents may effectively increase the efficacy of these therapies. This study aimed to compare through objective data the efficacy of topical tacalc...